PLUS1
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.00 | -1.46% | 67.50 | 65.00 | 70.00 | 68.50 | 67.00 | 68.50 | 160,114 | 12:32:23 |
| Industry Sector | Turnover (m) | Profit (m) | EPS - Basic | PE Ratio | Market Cap (m) |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 0.7 | -10.9 | -6.6 | - | 117 |
Angle (AGL) News Headlines
Angle News
| Date | Time | Source | Headline |
|---|---|---|---|
| 29/5/2020 | 07:00 | UKREG | Angle PLC Notice of Results |
| 12/5/2020 | 18:54 | ALNC |  Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects |
| 12/5/2020 | 07:26 | ALNCF | Alliance News Flash Headline |
| 12/5/2020 | 07:00 | RNSNON | Angle PLC CTC potential as biomarker in MET inhibitor trials |
| 04/5/2020 | 07:00 | RNSNON | Angle PLC Leading cancer centre publishes Parsortix workflow |
| 28/4/2020 | 07:00 | UKREG | Angle PLC Business Update |
| 17/4/2020 | 07:00 | UKREG | Angle PLC Parsortix performance in head and neck cancer |
| 31/3/2020 | 07:00 | UKREG | Angle PLC COVID-19 BUSINESS IMPACT UPDATE |
| 03/3/2020 | 18:58 | ALNC | Angle Parsortix Test Used To Help Discover Brain Metastasis |
| 03/3/2020 | 07:00 | UKREG | Angle PLC Assessing risk of brain metastasis in lung cancer |
1 Year Angle Chart |
Intraday Angle Chart |
